Abivax SA reported cash and cash equivalents of €530.4 million on 31 December 2025 giving the France-based biotech company sufficient funds to finance its operating expenses into the fourth quarter of 2027. This follows a successful public share offering in July that raised a net $700.3 million for the company on the back of unexpectedly robust results for two Phase 3 trials of its lead product obefazimod. Obefazimod is being studied in ulcerative colitis and Crohn’s disease, both subsets of inflammatory bowel disease. It is a small molecule drug that upregulates a microRNA known as miR124 in order to stabilise the immune response in patients with ulcerative colitis.
In its financial report for 2025, Abivax said it settled all tranches of its debt with its lenders and directed its cash reserves towards research and development. In the past year, it spent €177.8 million on R&D which represented 70.9% of operating expenses. This compares with outlays of €146.5 million, or 79% of operating expenses in 2024.
Abivax said its pivotal Phase 3 trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in the latter part of the second quarter. In the meantime, the company is building up its executive team in anticipation of a new product registration and commercialisation. It has appointed Michael Nesrallah, formerly of Takeda Pharmaceutical Company Ltd, as chief commercial officer.
“With a strong financial foundation, we are well positioned to execute on our strategic priorities and prepare for the future,” said Marc de Garidel, the company’s chief executive, in a prepared statement.
Copyright 2026 Evernow Publishing Ltd